Previous 10 | Next 10 |
5 Penny Stocks To Trade [or Avoid] Before The Weekend Investing in penny stocks has often proven to be a quick way of making substantial returns from a small account. Over the years, many investors have made fortunes through these stocks. Hence, there’s always a focus on finding the n...
SAN DIEGO , Jan. 21, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, today announced that a poster featuring safety and...
As of December 3, Russell 2000 Index (RUT, +7.3), which is a benchmark for small-cap stocks, is outperforming the S&P 500 (SP50, +5.2%) and Russell 3000 (RUA, +5.5%) benchmark indices in Q4 2019 (Exhibit 1). The Russell 2000 Index is a market-capitalization weighted index measuring the perfo...
SAN DIEGO , Dec. 9, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate an...
SAN DIEGO , Dec. 4, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including leukemia, prostat...
ResTORbio (NASDAQ: TORC ) -78% after lead candidate flunks study. More news on: resTORbio, Inc., Tonix Pharmaceuticals Holding Corp., Agile Therapeutics, Inc., Stocks on the move, Read more ...
Penny stocks are considered very risky by many investors. But what if I was to tell you that you can make them a lot less risky with a little due diligence? When trading penny stocks , you should be doing extensive research in companies you want to invest in as well as how the market is doing...
Exicure (NASDAQ: XCUR ) +30% on collaboration with Allergan in hair loss disorders. More news on: Exicure, Inc., Opera Limited, Ping Identity Holding Corp., Stocks on the move, Read more ...
Nano cap Trovagene (NASDAQ: TROV ) is up 17% premarket on increased volume in reaction to encouraging data from a Phase 2 clinical trial evaluating onvansertib, combined with J&J's Zytiga (abiraterone acetate) and prednisone, in patients with metastatic castration-resista...
SAN DIEGO , Nov.14, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including prostate, colorect...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...